Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 11Terminated 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Other hematologic neoplasm 2Head & Neck 2Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1Dermatologic 1Breast 1

Conditions

Kidney Neoplasms 2Carcinoma, Renal Cell 2Prostatic Neoplasms 1

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Reverse Transcriptase Polymerase Chain Reaction × Genitourinary × Clear all
NCT00788307 2023-04-18

Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy

Mayo Clinic

Phase 1 Terminated
8 enrolled
Genitourinary

Prostatic Neoplasms

NCT00747305 2015-10-22

Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery

Medical University of South Carolina

Phase 1 Terminated
17 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00589550 2015-06-08

PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Terminated
1 enrolled 2 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡